Purdue Pharma has tried to argue it was a “small player” in the U.S. market for prescription opioids utilizing the DEA database.
The DEA database shows Purdue sold 3.3% of all pain pills from 2006-2012. Purdue used this data to promote the idea that Purdue made a very small fraction of opioid nationally.
However, experts and a new ProPublica analysis note these numbers fail to take into consideration the potency and dose of pills into account.
Utilizing this data, Purdue actually has a 16% market share which is more than 5 times the number cited by the company.